SCHEMBL4213078

SCHEMBL4213078

O=c1[nH]cnc2c1sc1ccc(Cl)cc12

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIM1 P11309 18/20 0.59
PIM2 Q9P1W9 15/20 0.59
PARP1 P09874 1/20 0.53
CDC7 O00311 2/20 0.51
DYRK3 O43781 2/20 0.51
IGF1R P08069 2/20 0.51
CLK2 P49760 2/20 0.51
GSK3A P49840 2/20 0.51
GSK3B P49841 2/20 0.51
CSNK2A1 P68400 2/20 0.51
DYRK1A Q13627 2/20 0.51
PKN2 Q16513 2/20 0.51
PIM3 Q86V86 2/20 0.51
CLK4 Q9HAZ1 2/20 0.51
IKBKB O14920 1/20 0.51
AURKA O14965 1/20 0.51
DAPK3 O43293 1/20 0.51
ROCK2 O75116 1/20 0.51
RPS6KA5 O75582 1/20 0.51
PRKD3 O94806 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4215069 0.88 ALDH1A1 (0.53) PIM1PIM2PARP1CDC7DYRK3
SCHEMBL4219756 0.82 PIM1 (0.53) PIM1PIM2CDC7DYRK3IGF1R
SCHEMBL4207979 0.82 PARP1 (0.53) PIM1PIM2PARP1CDC7DYRK3
SCHEMBL4208656 0.80 LIMK1 (0.58) PIM1PIM2PIM3CLK4ALDH1A1
SCHEMBL4218616 0.79 PIM1 (0.55) PIM1PIM2PARP1CDC7DYRK3
SCHEMBL4208864 0.78 KRAS (0.51) PIM1PIM2PARP1CDC7DYRK3
SCHEMBL4208072 0.78 PARP1 (0.57) PIM1PIM2PARP1CDC7DYRK3
SCHEMBL19040891 0.77 PIM1 (0.46) PIM1PIM2PARP1CDC7DYRK3
SCHEMBL2303771 0.75 KDM4A (0.47) PIM1PIM2PARP1CDC7DYRK3
SCHEMBL4207983 0.73 PIM1 (0.49) PIM1PIM2PARP1CDC7DYRK3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090030196-A1 PIM KINASE INHIBITORS AS CANCER CHEMOTHERAPEUTICS ABBOTT LABORATORIES (US) 2009-01-29 US claimed
US-20170186971-A1 Compound, Light-Emitting Element, Display Device, Electronic Device, and Lighting Device SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) 2017-06-29 US disclosed
US-20170186971-A1 Compound, Light-Emitting Element, Display Device, Electronic Device, and Lighting Device SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) 2017-06-29 US disclosed
US-20090030196-A1 PIM KINASE INHIBITORS AS CANCER CHEMOTHERAPEUTICS ABBOTT LABORATORIES (US) 2009-01-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090030196-A1 PIM KINASE INHIBITORS AS CANCER CHEMOTHERAPEUTICS PIM1, PIM3, PIM2 PIM1 1/4885PIM2 3/4885PARP1 468/4885
US-20170186971-A1 Compound, Light-Emitting Element, Display Device, Electronic Device, and Lighting Device TPMT, DPYD, SUN2 PIM1 1096/4885PIM2 803/4885PARP1 747/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.